Foxo technologies on track to commence commercial rollout of vithar™ ai health coach in early 2024

Minneapolis--(business wire)--foxo technologies inc. (nyse american: foxo) (“foxo” or the “company”), a leader in the field of epigenetic biomarker technology, today provided a business update on the planned commercial rollout of its new direct-to-consumer (dtc) app, the vithar™ ai health coach. the company also expects to report its financial results for the three and nine months ended september 30, 2023, which the company anticipates will reflect a reduction in losses in excess of $10 million.
FOXO Ratings Summary
FOXO Quant Ranking